Here are some case studies of companies which collaborated with DCU on research projects or have emerged directly from DCU's research activities.
CertiVox is a leading web security company providing solutions to business, Government and end users. In 2012, CertiVox Labs was established to focus on the advancement of elliptic curve and pairing-based cryptography, through its own research team and academic collaborations, and through leadership of a number of standards committees. This ground breaking technology and expertise gives the company a huge competitive advantage in the marketplace, supporting the next generation of mobile devices and embedded systems which tomorrow’s internet will depend upon. The director of CertiVox Labs is former Head of the DCU’s School of Computing, Dr. Michael Scott. Dr. Scott has an international reputation in cryptography and is widely perceived as a leading authority on the subject of elliptic curve and pairing-based cryptography on which CertiVox’s services and solutions are based. CertiVox has already licensed the patents that were developed over the last decade at DCU and which were funded by Enterprise Ireland. At CertiVox Labs, Dr. Scott will continue to advance his cryptography research to maintain the company’s leadership position as the only company in the global market to provide easy-to-use, certificate-less security solutions. CertiVox Ltd. was founded in 2009 based on the simple belief that everyone deserves the right to secure their online information exchanges simply and easily. Their leading-edge technology and commitment to service has enabled industries around the world – including defence, government, legal and financial services – to protect and control their information exchanges through PCs, smart devices and in the cloud.
For more information on CertiVox Labs http://certivox.com/certivox-labs/
Pilot Photonics Ltd, is a DCU spin out and a privately held company offering unique optical comb source subsystems that will be a key enabler for the next generation of high density optical networking transmission solutions. With its patent pending technology, Pilot Photonics delivers robust and cost-effective optical comb sources, which emit highly stable, low line-width, phase-matched wavelength combs suitable for multicarrier optical transmission systems including coherent optical OFDM, Coherent WDM and Nyquist WDM. The company has recently announced the appointment of Dr. Stan Lumish as Chief Executive Officer and Chairman of its Board of Directors. Dr. Lumish replaces Dr. Philip Perry, founding CEO, who will remain on the board of directors and return to Dublin City University to pursue optical transmission research. “We are extremely excited to have Dr. Lumish join the company,” says Dr. Frank Smyth, Pilot Photonics CTO. “He brings an invaluable wealth of experience, industry connections and business acumen at an important time in the company’s development. Stan will help us take the business to the next level.” Dr. Stan Lumish has over 25 years experience in the field of optical networking. He has held leadership positions at AT&T Bell Labs, Lucent Technologies and JDSU, including as the corporate CTO of JDSU. Pilot Photonics, Ltd. is headquartered at Invent, which is located on the Dublin City University campus.
For more information visit www.PilotPhotonics.com
StableLab Ltd. (formerly Epona Biotech) is an Irish company that specialises in developing solutions for the equine healthcare industry. StableLab was introduced to the Biomedical Diagnostics Institute (BDI) based in DCU, by the Institute’s Commercialisation Development Manager. The BDI carries out cutting-edge research in next-generation biomedical diagnostic devices and has developed strong capability in point of care assay development. The BDI has propriety capability in coagulation testing and has now licensed a patented coagulation assay to StableLab. The company will further develop this test to provide improved veterinary diagnostics at the point of need, which will ultimately lead to improved equine healthcare solutions. The assay was originally developed by Professor Tony Killard and Dr. Magdalena Dudek at the BDI in Dublin City University and will be further developed by StableLab to measure the concentration of fibrinogen in equine blood samples. Fibrinogen is a key component of the acute phase inflammatory response in horses and the results of the assay can be read by eye alone, negating the need to use complex machine readers. Commenting on the license, Dr. Henrich Anhold, Founder and CEO of StableLab Ltd., stated “The BDI has a unique academic-industry-clinical partnership and their research teams are developing cutting edge diagnostic technologies and providing real tangible healthcare solutions. Dr. Conor Burke, Associate Director of Commercialisation for BDI, added “This is an excellent example of how the BDI leverages its multi-disciplinary research in order to benefit an indigenous Irish company and achieve tangible economic impact.”
For more information http://www.stablelab.com/